The QualityStocks Daily Thursday, July 1st, 2021

Today's Top 3 Investment Newsletters

MissionIR(MEDS) $7.17 +62.22%

Tip.us(SIBE) $0.0624 +38.67%

MarketClub Analysis(BLIN) $5.75 +33.72%

The QualityStocks Daily Stock List

Synchronoss Technologies (SNCR)

Zacks, The Street, StreetInsider, StockMarketWatch, InvestorPlace, TraderPower, BUYINS.NET, Schaeffer's, MarketBeat, SmarTrend Newsletters, MarketClub Analysis, Barchart, Marketbeat.com, Cabot Wealth, Daily Trade Alert, Profit Confidential, Goldman Small Cap Research, BestOtc, Trading Tips, CRWEFinance, CRWEPicks, CRWEWallStreet, PennyOmega, DrStockPick, Greenbackers, INO.com Market Report, Trades Of The Day, TopStockAnalysts, StreetAuthority Daily, StockHotTips, QualityStocks, PennyToBuck and Darwin Investing Network reported earlier on Synchronoss Technologies (SNCR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Synchronoss Technologies, Inc. (NASDAQ: SNCR) (FRA: H6K) is a software and services firm that is engaged in the provision of messaging, digital, cloud and network management platforms, solutions and products in the Asia Pacific, Africa, the Middle East, Europe and the Americas.

The firm has its headquarters in Bridgewater, New Jersey and was incorporated in 2000 by Stephen G. Waldis and James M. McCormick. It operates in the technology sector, under the software and tech services industry, in the software sub-industry.

The company provides software-based solutions activated for connected devices across the globe. The majority of the company’s revenue is derived from the U.S., with the remaining portion coming from other nations across the globe. It sells and markets its services via its strategic partners and a direct sales force.

The enterprise’s solutions are delivered through the Integrated Life, Enterprise, Synchronoss Personal Cloud and Activation Services platforms, which are available on-demand and are scalable. Its solutions include optimizing, managing, procuring, and telecom network infrastructure designing solutions; experience management, orchestration, development, workflow design and customer journey solutions; multi-channel messaging, peer-to-peer communications and application-to-person commerce solution; and content engagement for user generated content, content transfer, device set up, backup and cloud sync solutions. These solutions are mainly provided to original equipment manufacturers, retailers, enterprises and mobile carriers.

The firm’s Personal Cloud Solution was recently selected to be used in Indonesian universities through its partnership with Telkomsigma. This will not only extend the company’s consumer reach but also avail more strategic opportunities for the firm which it can capitalize on, not only for investments but also for revenue.

Synchronoss Technologies (SNCR), closed Thursday's trading session at $3.48, off by 3.0641%, on 2,111,020 volume with 9,289 trades. The average volume for the last 3 months is 1.202M and the stock's 52-week low/high is $2.3499999/$6.59000015.

Adomani (ADOM)

MarketBeat, StockMarketWatch, TraderPower, BUYINS.NET, StreetInsider, SeeThruEquity Research and QualityStocks reported earlier on Adomani (ADOM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Adomani Inc. (OTCQB: ADOM) is engaged in the design, manufacture, installation and provision of zero-emission electric vehicles and drivetrain systems for fleet vehicles as well as in the manufacture of kits that convert gas engines into hybrid and electric engines.

The firm has its headquarters in Corona, California and was incorporated in 2012, on August 12th by Edward Riggs Monfort. It operates in the consumer discretionary sector, under the consumer discretionary products industry, in the automotive sub-industry. The firm serves consumers in the U.S.

The enterprise provides wiring, brackets, motor drive systems, battery packs and controllers for trucks and buses. Its services and products include cab-over-engine trucks, zero-emission electric school buses, fold-down rear seats, climate control, Neighborhood Electric Vehicles which are enclosed vehicles using seatbelts, e-trikes, zero-emission vehicles and chassis. It also produces transit and shuttle buses and walk-in delivery vans. Its shuttle buses are built with a hybrid drivetrain while the walk-in delivery vans are commercial vehicles. On the other hand, the cab-over-engine truck is designed for various logistical requirements while the transit buses come in different models, which include EV450, EV400, EV350, EV300 and EV250. The enterprise’s hybrid drivetrain systems are available in both full-traction format and in assistive hybrid format, for use in commercial and private fleet vehicles of every size.

The firm, which recently entered into a merger agreement with Envirotech Vehicles, is working on becoming the first mover in the smaller commercial E.V. space. This move capitalizes on the Biden Administration’s aim to replace government vehicles, most of which belong to the 3, 4 and 5 classes, with electric ones. Becoming the first mover will bring in a lot of investments into the firm as well as huge contracts, which will be good for the company’s growth.

Adomani (ADOM), closed Thursday's trading session at $0.3236, up 9.5835%, on 1,388,512 volume with 396 trades. The average volume for the last 3 months is 920,380 and the stock's 52-week low/high is $0.132499992/$0.969900012.

Earth Science Tech (ETST)

NetworkNewsWire, QualityStocks, StocksToBuyNow, CannabisNewsWire, SmallCapRelations, Tip.us, MissionIR, TraderPower, SeriousTraders, PoliticsAndMyPortfolio.com, Penny Stock 101, PennyStockLocks, StockRockandRoll, Penny Stock General, Juicy Penny Stocks, Wall Street Mover, Shiznit Stocks, SeeThruEquity Research, Stock Commander, StockRunway, Penny Stock Titans, Tiny Gems, InvestorPlace, TopPennyStockMovers, PennyDoctor, Monster Alerts, Wallstreet Profiler, Equity Observer, GoldminePennyStocks, Hot Stock Profits, HotStockProfits, SmallCapVoice, StockMarketIntel, King Penny Stock Fortune, Penny Stock Prodigy, Money Morning, Cannabis Financial Network News, Value Penny Stocks, OtcShortReport, OTCStars.com, Promotion Stock Secrets, Seeking Penny Stocks, RedChip, Whisper from Wall Street, Penny Stocks Profile and SmallCapGrowth reported earlier on Earth Science Tech (ETST), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Earth Science Tech, Inc. (OTCQB: ETST) is a biotech firm that is engaged in delivering bioceuticals, nutraceuticals and dietary supplements in the alternative medicines, cosmetics, supplements, nutrition, wellness and health areas across the globe.

The firm has its headquarters in Doral, Florida and was incorporated in 2010, on April 23rd. Prior to its name change in April 2014, the firm was known as Ultimate Novelty Sports Inc. It operates as a part of the pharmaceutical manufacturing industry, under the health care sector, in the biotech and pharma sub-industry. The firm has two companies in its corporate family.

The enterprise is focused on delivering dietary and nutritional supplements for treating aging, nausea, weight management, depression, memory loss, high blood pressure, seizures, inflammation, joint pain and chronic pain.

The company’s products include functional foods, homeopathies, personal care products, botanicals, herbs, minerals and vitamins, among other products. In addition, it provides CBD oil to retailers in the vaping industry as well as other cannabinoid products and also retails sport, wellness and health products. The company provides its products via the internet and in its retail store which is found in Coral Gables, Florida. It markets its products in various delivery forms and formulations, which include whole herbs, powders, sprays, creams, liquids, chewables, soft gels, tablets and capsules.

As cannabis and cannabis products are legalized for use and become more popular in different parts of the world, the company may record an increase in sales, which will bring in more revenue. Their variety of products will also help extend their consumer reach, which may in turn boost investments into the firm.

Earth Science Tech (ETST), closed Thursday's trading session at $0.0215, up 4.3689%, on 33,411 volume with 5 trades. The average volume for the last 3 months is 382,616 and the stock's 52-week low/high is $0.0118/$0.100000001.

Nexteligent Holdings (NXGT)

We reported earlier on Nexteligent Holdings (NXGT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Nexteligent Holdings Inc. (OTC: NXGT) is a healthcare professional services company that acts as an aggregator of technology companies and professional healthcare services.

The firm has its headquarters in Avon, Connecticut and was incorporated in 1997, on June 4th. It operates in the technology industry, under the software and tech services industry, in the software sub-industry and serves consumers across the globe.

The company operates via the financial services and telemedicine solutions divisions. The former division is engaged in the provision of denials recovery and revenue cycle management solutions for long term care operators, clinics, doctor groups and hospital systems. In addition to this, this division provides turnkey solutions for preventive care services like remote tele-monitoring, behavioral health, annual wellness visits, transitional care management and chronic care management. On the other hand, the latter segment is involved in managing and developing remote care and technology programs whose objectives are to improve productivity, contain costs and boost the quality of medical encounters at healthcare institutions that serve the eldercare sector as well as not-for-profit organizations and municipalities.

The enterprise’s software applications store, collect and analyze operating data to diagnose problems, determine performance and recommend corrective action. This is in addition to eliminating redundancy, increasing revenue and streamlining workflows.

The firm recently hired Corporate Finance Associates Worldwide, which will provide the firm with assistance on acquisitions. Its CEO noted that this move will facilitate the company’s achievement of its goals, having acquired Professional Revenue Management Services in November 2020, which strengthened the range of services the company offers to clients. The firm is now focused on its growth strategy, which is centered on acquisitions. This move’s success is bound to not only grow the firm but also boost investments.

Nexteligent Holdings (NXGT), closed Thursday's trading session at $0.048, off by 26.1538%, on 724,628 volume with 56 trades. The average volume for the last 3 months is 607,518 and the stock's 52-week low/high is $0.020999999/$0.179000005.

Sundial Growers (SNDL)

Schaeffer's, InvestorPlace, MarketBeat, BUYINS.NET, The Street, QualityStocks, Trades Of The Day, Daily Trade Alert, StreetInsider, The Online Investor, StocksEarning, StockMarketWatch, Investopedia, Early Bird and CNBC Breaking News reported earlier on Sundial Growers (SNDL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sundial Growers Inc. (NASDAQ: SNDL) (FRA: 14K) operates as a pharmaceutical firm that is engaged in the marketing and production of marijuana and a variety of marijuana extracts and products, for the adult-use marijuana market in Canada.

The firm has its headquarters in Calgary, Canada and was founded in 2006 by Stanley J. Swiatek. It operates as part of the pharmaceutical manufacturing industry, under the health care sector, in the biotech and pharma sub-industry. The firm serves consumers in Canada and has two companies in its corporate family.

The company combines horticultural methods and tried-and true heartland farming to grow various marijuana strains and is focused on the consistency of marijuana. It operates through the Corporate, Ornamental Flowers and Cannabis segments. The former segment represents corporate items and activities that have not been allocated to reportable operating segments while the Ornamentals segment is involved in the legacy operations of the company’s Bridge Farm. On the other hand, the latter segment is involved in the legal growing and distribution of marijuana products under federally regulated licenses that have been issued by Health Canada.

The enterprise distributes and produces inhalable products like vapes, pre-rolls and flower. It provides its products under the Grasslands, Palmetto, Sundial Cannabis and Top Leaf brands.

Projections show that by 2026, the cannabis market will be valued at about $90 billion. Legalization of the herb across various regions will also boost the market’s growth. This firm is well poised to capitalize on this and emerge as bigger and better, which will be good for the company’s shareholders.

Sundial Growers (SNDL), closed Thursday's trading session at $0.92, off by 3.0558%, on 101,828,279 volume with 85,350 trades. The average volume for the last 3 months is 212.58M and the stock's 52-week low/high is $0.138099998/$3.96000003.

Troubadour Resources, Inc. (TROUF)

We reported earlier on Troubadour Resources, Inc. (TROUF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Troubadour Resources, Inc. engages in the acquisition, exploration, and evaluation of mineral properties in Canada. The Company’s focus is on copper in British Columbia. An experienced team of professionals with proven records of accomplishment as mine finders manage Troubadour Resources. The Company previously went by the name Grandore Resources, Inc. It changed its name to Troubadour Resources, Inc. in February of 2017. Incorporated in 2012, Troubadour Resources is headquartered in Vancouver, British Columbia. The Company lists on the OTC Markets and the TSXV.

Troubadour Resources has its Amarillo Copper Project. The Amarillo Property comprises 9 mineral claims encompassing 5,449 hectares. The Amarillo Project is positioned 10km to the south of the past producing Brenda Mine, and proximal to Highland Valley, Craigmont, and Copper Mountain mines. It is situated in the core of a major mining district.

The Amarillo Copper Property is strategically located close to major low cost copper producers. This gives it a distinct advantage for future development potential. The three targets are the Trench Anomaly, the Copper Rich Skarn Deposit, as well as the North Copper Anomaly.

The multi-element signature of the Amarillo Project area is consistent with a large multiphase mineralizing system. It is very similar to some of the neighbouring world-class mining operations. Prior completed drilling encountered mineralization and alteration indicative of an alkalic porphyry system.

Troubadour Resources announced this past October that it acquired by staking an additional 420 hectares (ha) of highly prospective ground contiguous to its Texas property located in the Greenwood Mining District. The Texas property now covers an area of 2,186 ha. The newly acquired Texas gold property diversifies Troubadour Resources’ commodity emphasis and complements the Company's copper project, the Amarillo property.

Troubadour Resources, Inc. (TROUF), closed Thursday's trading session at $0.175, up 25%, on 116,570 volume with 24 trades. The average volume for the last 3 months is 34,830 and the stock's 52-week low/high is $0.0208/$0.206799998.

PASSUR Aerospace, Inc. (PSSR)

QualityStocks, MarketBeat, Zacks, FeedBlitz, StocksEarning, PoliticsAndMyPortfolio.com, M2 Communications and InvestorPlace reported earlier on PASSUR Aerospace, Inc. (PSSR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

PASSUR® Aerospace, Inc.’s corporate mission is to improve global air traffic efficiencies through connecting the world’s aviation professionals onto a single aviation intelligence platform. The Company is an international leader in digital aviation operational excellence. PASSUR provides predictive analytics and decision support technology for the aviation industry, chiefly to improve the operational performance and cash flow of airlines and the airports where they operate.

The Company provides its solutions to the largest airlines and airports around the world including the USA, Canada, Europe, and Latin America. A New York Corporation established in 1967, PASSUR Aerospace is based in Stamford, Connecticut.

The Company owns and operates the largest commercial passive radar network worldwide. PASSUR provides aircraft position updates every 1 to 4.6 seconds, powering a proprietary database that is accessible in real-time, and delivers timely and accurate information and solutions through the Company’s industry leading algorithms and business logic included in its products. PASSUR’s information solutions are used at the five largest North American airlines, by more than 60 airport customers. Furthermore, these information solutions are used at the top 30 North American airports, by greater than 100 business aviation customers, and by the U.S. government.

PASSUR Aerospace maximizes airspace, runways, as well as gate usage, by using predictive analytics to ascertain how airports should be configured to get the most out of their capacity. The Company helps airlines, airports, and air traffic control prioritize departures to maximize capacity and minimize delays, by helping to ensure that all three stakeholders work together with the most accurate, timely information.

In addition, 53 percent of all U.S. domestic commercial flights are managed with PASSUR predictive analytics for predicted arrival times, through using years of archived data, and real-time airspace analysis. This enables airlines and airports to always be ready for the aircraft.

PASSUR Aerospace has its new platform, AR\VA™. AR\VA represents the total redesign and relaunch of the PASSUR platform. This enables customers to predict, prevent, and also manage disruptions in the air and on the ground. This enables them to be even more proactive because of advanced intelligence.

PASSUR Aerospace, Inc. (PSSR), closed Thursday's trading session at $0.84995, up 21.4214%, on 16,760 volume with 13 trades. The average volume for the last 3 months is 2,514 and the stock's 52-week low/high is $0.219999998/$2.25.

SpeakEasy Cannabis Club Ltd. (SPBBF)

We reported earlier on SpeakEasy Cannabis Club Ltd. (SPBBF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

SpeakEasy Cannabis Club Ltd. concentrates on producing medical cannabis in Canada. It owns roughly 290 acres of land in Rock Creek, British Columbia. SpeakEasy represents a collective of the leading cannabis growers in Canada, sharing decades of knowledge and experience to produce first-class product. Fundamentally, SpeakEasy is an incubator designed to support industry-leading talent with the shared knowledge, resources, and passion of its entire operation. The Company lists on the OTC Markets. SpeakEasy Cannabis Club has its corporate office in Vancouver, British Columbia.

The Company’s 290-acre facility is in the South Okanagan Valley. SpeakEasy is the only licensed producer applicant in British Columbia’s renowned ‘Golden Mile’. The Company’s innovative business model enables each grower to operate independently. It also gives them the freedom to develop each strain to perfection.

Mr. Marc Geen is Founding Chief Executive Officer (CEO) & Adviser to the Board of Directors. He is a 4th-generation British Columbia farmer. Mr. Geen has been active in the legal medical marijuana industry for over a decade, consulting, complying with, and participating in the MMAR, MMPR, and ACMPR programs. Before co-founding Speakeasy Cannabis Club Ltd., he spent 14 years as Head of Operations for Kettle Mountain Ginseng Ltd.

Dr. Bin Huang is CEO & Director of SpeakEasy Cannabis Club. Dr. Huang joined the Company in June 2019 as CEO. She is an experienced life-sciences executive with experience in strategy and new business development, financing and public markets, corporate governance, and operations management in North America and Asia. Dr. Huang’s work experience includes 18 years as CEO of life-sciences companies, most recently CEO of Emerald Health Therapeutics, Inc.

SpeakEasy Cannabis Club has announced that it signed a non-binding Letter of Intent (LOI) with M&J Orchards Ltd. to plant 50 acres of hemp in 2020 on M&J’s property. SpeakEasy’s property has already undergone stringent approval processes from the Agricultural Land Reserve, Federal, Provincial, Municipal governments and Health Canada for the cultivation of THC (Tetrahydrocannabinol) bearing cannabis. SpeakEasy finds it necessary to lease land so it can grow industrial hemp and secure a supply of CBD (cannabidiol) bearing hemp that would meet its biomass standards.

The expectation is that demand for CBD will be more than the Company could possibly grow on its land package. Thus, strategic partnerships with land owners and operators to produce industrial hemp is vital for SpeakEasy to keep up with demand. Throughout the 2020 season, it will continue to develop its Phase 2 outdoor grow facility on the remaining land suitable for growing cannabis on its 290 acre property. The Company expects it to be licenced and ready for the 2021 grow season.

SpeakEasy Cannabis Club also announced the appointment of Mr. Bill Fleming, an independent Director, to its Board of Directors at its 2020 Annual General Meeting. Mr. Fleming has founded and served as CEO for several entrepreneurial companies. He has served with senior executive teams dealing with equity and debt financings. Mr. Fleming has developed corporate strategies for a broad array of companies, from family-owned businesses to multi-national companies. At present, Mr. Fleming serves as President of Mernova Medicinal, Inc., which recently sold to Switzerland based Creso Pharma Limited.

SpeakEasy Cannabis Club Ltd. (SPBBF), closed Thursday's trading session at $0.58, up 22.1053%, on 8,100 volume with 9 trades. The average volume for the last 3 months is 21,743 and the stock's 52-week low/high is $0.000099999/$1.24989998.

Oliveda International, Inc. (OLVI)

QualityStocks, StocksEarning, StockHideout, Stock Guru, ProTrader, Stock Commander, KingPennyStocks, Penny Stock 101, Penny Stock General, PennyStockLocks, BullFreak, Small Cap Firm, Winston Small Cap, StockRockandRoll, StockRunway, StockTradingNetwork and Shiznit Stocks reported earlier on Oliveda International, Inc. (OLVI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Oliveda International, Inc. is a leading international natural cosmetics innovator in the premium segment. It has also developed a globally innovative wearable beauty and health technology. Through subsidiary operations, the Company is the largest investor in eco-certified mountain olive trees and the largest conservationist in Arroyomolinos de Leó, Spain. German real estate investor Mr. Thomas Lommel founded Oliveda International in 2003. Oliveda International is based in Santa Monica, California.

The Company generates online sales and has a worldwide branch network of 650 retail stores. Its wholly-owned Oliveda Deutschland GmbH subsidiary operates flagship stores, Olive Tree Pharmacy, in Berlin and Dusseldorf. It has plans to open new locations in Los Angeles, Taipei and Seoul.

Overall, Oliveda International believes that it will be able to operate a total of 60 of its own flagship stores around the world. In addition, it believes that it will be able to increase the retail store network globally to 1,200 over the next five years.

On September 1, 2015, Oliveda International opened its first flagship Store in the Neue Schönhauser Str. 11 in Berlin-Mitte. With this opening, the concept of the Company’s Olive Tree Pharmacy came to fruition. In Olive Tree Pharmacy Stores, visitors are counseled in the holistic advantages of Oliveda International’s Olive Tree Therapy, and given a sense of its encompassing effects. Furthermore, the Company supplies visitors with Olive Tree Home Therapy Sets, custom-made to suit their personal needs.

Oliveda International launched many new products in 2019. This included its Beauty Molecule that was met with immediate success, entering Oliveda’s Top 10 bestselling products within just a few weeks. Furthermore, new companies and brands were developed in 2020, including LA DOPE, Olive Tree People, and Oliveda America. New innovative technologies were also developed, as well as sales contracts for more than 20,000 of the Company’s own mountain olive trees.

Oliveda International, Inc. (OLVI), closed Thursday's trading session at $0.0997, up 32.9333%, on 26,939 volume with 12 trades. The average volume for the last 3 months is 9,728 and the stock's 52-week low/high is $0.012799999/$0.649999976.

Petrogress, Inc. (PGAS)

QualityStocks, NetworkNewsWire, StocksToBuyNow, SeriousTraders, PennyDoctor and MarketBeat reported earlier on Petrogress, Inc. (PGAS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Petrogress, Inc., by way of its subsidiaries, operates as an integrated merchant of petroleum products. The Company is an independent Oil energy and Shipping company. It specializes in oil exploration, production, trade and sea transportation with global operations throughout Europe, Africa and the Middle East. The Company owns and operates a fleet of tankers from its base in the historic Port of Piraeus through a series of Marshall Islands subsidiaries. Petrogress is based in Delaware and New York and lists on the OTC Markets.

The Company operates mainly as a holding company for its wholly-owned subsidiaries. Petrogress concentrates on the supply and trade of light petroleum fuel oil, refined oil products and other petrochemical products to local refineries in West Africa and Mediterranean countries.

In addition, Petrogress operates service and shipping facilities at the Port of Limassol in Cyprus and the Port of Tema, Greater Accra, in Ghana. The Company is actively looking for expansion opportunities. This includes in operating and developing natural gas production and transmission facilities along with LNG processing in the United States, refinery operations in north and West Africa, and the transport and sales of LNG in Europe.

For Upstream - oil resources and exploration, Petrogress has its Petrogres Oil & Gas Energy, Inc. subsidiary. For Midstream - product fleet carriers, the Company has its Petronav Carries, LLC subsidiary. Regarding Downstream – processing and refining, it has its J/V PGO & PGL – Ghana subsidiary. Furthermore, regarding Marketing – purchases and sales, Petrogress has its Petrogres Co. Limited subsidiary.

In December of 2018, Petrogress announced that its Petrogress Int’l, LLC (PIL) subsidiary entered into a Partnership Agreement with Deliman Oil Company Limited, a Ghanaian corporation. This Agreement is to jointly create and co-operate a Ghanaian corporation to be called PG&D Fueling. PG&D will operate and manage gas/refueling stations in Ghana, Burkina Faso and Niger and associated storage and distribution operations.

The expectation is that PG&D will initially operate and manage 65 gas stations now owned by Deliman in Ghana and Burkina Faso. The petrochemical products to be distributed via PG&D managed gas stations will be supplied by PIL affiliate company Petrogres Co. Limited, via its partnership with Platon Oil Refinery in Ghana.

Recently, Petrogress announced that its PIL subsidiary entered into an Exclusive Distribution Agreement with Dana Lubricants Factory LLC (Dana Lubes), a United Arab Emirates (UAE) based lubricant oil manufacturer. This agreement designates PIL as the exclusive agent for distribution of products manufactured and branded by Dana Lubes throughout western Africa.

Petrogress, Inc. (PGAS), closed Thursday's trading session at $0.095, up 22.8978%, on 978,544 volume with 126 trades. The average volume for the last 3 months is 249,193 and the stock's 52-week low/high is $0.0104/$0.314999997.

MMEX Resources Corp. (MMEXD)

QualityStocks, Promotion Stock Secrets, SmallCapNetwork, Outcast Traders, Stock Traders Chat, TopPennyStockMovers and Real Pennies reported earlier on MMEX Resources Corp. (MMEXD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

MMEXD Resources Corp. focuses on the acquisition, development and financing of oil, gas, refining and infrastructure projects in Texas and South America. The Company established to engage in the exploration, extraction, refining and distribution of oil, gas, petroleum products and electric power. A development-stage company, MMEXD Resources is headquartered in Fort Stockton, Texas.

MMEXD’s main areas of interest include the acquisition and potential development of refining, oil & gas assets in Texas, and the acquisition of oil and gas properties in Peru. In addition, main areas of interest include crude, oil and product export opportunities in Latin America, and the development of terminals, storage, refining, oil & gas in Brazil.

The Company’s projects include the Pecos County Refinery Project, Fort Stockton, Texas. Phase 1 of this project is a 10,000 BPD Crude Distillation Unit. Phase 2 is a 100,000 BPD Large-Scale Refinery. The project is in Sulfur Junction, about 20 miles northeast of Fort Stockton. The project is strategically positioned close to oil production in West Texas, with storage capability.

MMEXD Resources signed an off-take agreement with Pilot Thomas Logistics. The off-take agreement is for the sale of its diesel fuel production from Phase 1 of the MMEXD refinery project in Pecos County. In November 2017, MMEXD Resources broke ground on Phase 1 of the MMEXD Refinery Project in Pecos County. The agreement provides for Pilot Thomas Logistics to obtain 100 percent of the diesel production from Phase 1, roughly 4,200 barrels per day, for markets in the Permian Basin area principally for use in drilling operations.

MMEXD Resources intends to develop a solar power project to provide electric power to its planned 10,000 barrel-per-day (BPD) crude distillation unit and its full-scale crude oil refinery in Pecos County near Fort Stockton, Texas.

MMEXD Resources and Blanchard Industrial, LLC (BIL) previously announced that BIL will be the overall EPC contractor to complete the detailed engineering and to construct the planned Pecos County Crude Distillation Unit refinery earlier announced by MMEXD. BIL is an industry leader in design, engineering, procurement and construction (EPC) solutions.

MMEX Resources Corp. (MMEXD), closed Thursday's trading session at $4.00, off by 33.33%, on 25,423 volume with 268 trades. The average volume for the last 3 months is 289.867M and the stock's 52-week low/high is $0.009999999/$249.00.

Celsius Holdings Inc. (CELH)

MarketBeat, StockOodles, Kiplinger Today, TradersPro, InvestorPlace, MarketClub Analysis, BUYINS.NET, PennyStocks24, Schaeffer's, SmallCapVoice, Zacks, The Street, TraderPower, Trades Of The Day, Wealth Insider Alert, StreetInsider, The Online Investor, QualityStocks, The Wall Street Transcript, TopPennyStockMovers, FreeRealTime, Daily Trade Alert and StockMarketWatch reported earlier on Celsius Holdings Inc. (CELH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Celsius Holdings (NASDAQ: CELH), maker of the global fitness drink Celsius(R), announced that it has officially closed on its previously announced underwritten public offering. The offering was comprised of 7,391,408 shares of common stock, including 6,257,455 shares of common stock offered by certain selling stockholders of Celsius Holdings and 1,133,953 shares of common stock offered by Celsius Holdings; included in those shares were 873,141 shares pursuant to the partial exercise of the over-allotment option granted to the underwriters. According to the announcement, the shares were sold at $62.50 per share, and the company will see $462 million in gross proceeds from the transaction. The company plans to use the net proceeds for general corporate purposes. Roth Capital Partners acted as co-manager for the offering.

For more information, visit www.CelsiusHoldingsInc.com.

Celsius Holdings is a fast-growing company in the functional energy drink and supplement categories in the United States and internationally, engaged in the development, marketing, sale and distribution of functional calorie-burning supplements that offer clinically proven and innovative formulas meant to improve the health and wellness of its consumers.

Celsius offers five beverage lines that include Celsius Originals, Celsius Heat(TM), Celsius BCAA+Energy, Celsius On-the-Go and Celsius Sweetened with Stevia. Celsius drinks have no sugar, preservatives, aspartame, or high-fructose corn syrup, and its products are non-GMO, with no artificial flavors or colors. The Celsius line of products is certified kosher and vegan. Celsius is also soy and gluten free and contains very little sodium.

Celsius Holdings Inc. (CELH), closed Thursday's trading session at $72.73, off by 4.4158%, on 841,695 volume with 13,750 trades. The average volume for the last 3 months is 1.226M and the stock's 52-week low/high is $10.7600002/$83.

The QualityStocks Company Corner

DSG Global Inc. (OTCQB: DSGT)

The QualityStocks Daily Newsletter would like to spotlight DSG Global Inc. (DSGT).

DSG Global (OTCQB: DSGT)an emerging player in the electric vehicle (“EV”) segment with a large lineup of affordable and diverse vehicles, and its subsidiary, Imperium Motor Company, were featured in a recent “Jalopnik” article. The article, titled “A Chinese Appliance Company Makes America’s Newest EV,” noted that a Chinese car shop had quietly set up in Northern California with the opening of Imperium Motor Company’s experience center, which held its grand opening on June 18. The article notes that the company, which is perhaps best known for selling TVs, has entered the U.S. market with its electric SUV. “Now, Car News China does say that the ET5 is Imperium’s first offering here,” the article, which was written by Raphael Orlove, states. “And I could only find pictures of an ET5 in real life on Imperium’s Facebook page. The company itself states in a press release that it has no less than 25 electric offerings for us Americans to check out: ‘Designed to create interest in IMC’s impressive line of EVs, the event encouraged attendees to drive and ride in 25 different electric-powered units, including the company’s flagship Imperium ET5 SUV, the Van Maxx, the Urbee 4, the new Jonway T3 Cargo, the Urbee Security LSV, the Raptor Golf Cart, the Rumble lineup, the Imp Chimp and other models. Unlike many companies jockeying for position in the EV space, IMC has existing models and inventory already on hand, ready to be sold.’” To view the full article, visit https://ibn.fm/XdTaM

DSG Global Inc. (OTCQB: DSGT) is an emerging global technology company with interconnecting businesses in fast growing market sectors. With roots in the golf industry, the company specializes in golf fleet management and is moving quickly into road-ready electric vehicles for delivery in the third quarter of 2021.

In 2019, the company secured exclusive North America distribution rights for Jonway Automobile Co. road-ready electric vehicles (EVs). Jonway, based in Zhejiang, China, began manufacturing new vehicles s in 2003 and today produces Electric powered Cars, Trucks, Vans, SUV’s, and Scooters. Jonway vehicles are exported to more than 80 countries and are built to comply with U.S. safety and environmental standards.

These vehicles are being sold via DSG’s wholly owned subsidiary, Imperium Motor Company (IMC). The move into consumer vehicles capitalizes on the company’s strength in the selection and distribution of EVs, the ability to work with large manufacturers and in application of proprietary technology unique to DSG. DSG’s advanced fleet tracking can be integrated into Jonway EVs to offer a customized scalable and integrated solution to meet the needs of small businesses and large enterprises.

The Future is Electric

With decades of EV experience in golf, including distribution of highly advanced carts, DSG recognized the huge chasm between consumer interest in acquiring road ready EVs versus current EV models’ lack of availability and affordability. As such, the company focused on becoming a distribution and EV brand management company unencumbered by the manufacturing process. The manufacturers take responsibility for building vehicles to DSG’s specifications and fulfillment of regulatory and licensing requirements.

DSG has also established a distribution agreement with Skywell New Energy Automobile Group Ltd., an Asian-based EV manufacturer. Skywell will supply DSG with SUV’s, Passenger Vans, Cargo Vans, Commercial Vehicles and Buses that will be fully certified for use in the United States.

Brands

Imperium Motor Company (IMC) seeks to transform the way the world drives by making greener transportation available to everyone. IMC is an EV sales and marketing company that distributes directly to consumers and through third party distributors, offering a wide variety of affordable vehicles equipped for the North American market. The company’s emphasis is on great design, a green mindset, performance and functionality. Its vehicles include 26 models of high-speed, mid-speed and low-speed electric vehicles including cars, trucks, SUVs, vans, buses and scooters.

Vantage Tag Systems (VTS) is a global leader in the design, manufacture, and marketing of fleet management solutions for the golf industry. VTS has developed the TAG suite of products that represents the industry’s first completely modular fleet management solution. The company’s patented analytics, mobile touch screen GPS units and electric golf carts are sold around the world through a network of established distributors and partnerships with notable brands in fleet and equipment manufacture. VTS solutions also have applications in managing commercial, agricultural, military and government fleets. VTS is a wholly owned subsidiary of DSG Global.

Market Outlook

The global EV market was valued at $273 billion in 2017, according to Fortune Business Insights, and is projected to exceed $987 billion by 2027, with a projected CAGR of 17.4 percent. The relative high manufacturing costs of EVs compared to gasoline-powered vehicles and the resulting higher sticker price to consumers are major obstacles to near term market adoption.

The global e-bike market is estimated to grow to $70 billion by 2027 from its current valuation of $41.1 billion. An estimated 130 million e-bikes are expected to be sold globally over the next two years. The U.S. imported approximately 600,000 e-bikes in 2020, according to the Light Electric Vehicle Association, and its analysts expect that number will grow substantially in 2021.

Management Team

Robert “Bob” Silzer is the CEO of DSG Global. He is a serial entrepreneur who turns technology ideas in high growth industries into profitable businesses. With roots in the golf industry, he founded Vantage Tag Systems in 2008. Vantage Tag Systems is now a DSG subsidiary specializing in GPS-enabled fleet management.

Zahir Loaiza is the interim CFO of DSG Global. She assumed the role in March 2021, after having previously served as the company’s Corporate Controller. Her diverse international experience includes working at a publicly traded mining company, several law firms and more in the U.S., Canada and South America. Prior to pursuing a career in corporate finance, she was the owner of two retail entities.

Rick Curtis is the president and COO of Imperium Motor Company, the automotive subsidiary of DSG Global. His 40-year background in the automotive industry includes manufacturing, vehicle distribution, parts distribution, service management, dealer development and executive management of dealer groups. Prior to joining Imperium, Mr. Curtis served as president of Mullen Technologies and grew the company into a world class provider of electric vehicles, battery technology and energy storage systems.

William “Bill” Rex is president of Imperium Motor’s EV Bus and Motor Home Division. He has more than 40 years’ experience at suppliers of buses/electric buses, motor homes, trucks, specialty vehicles and batteries. He is the founder of Rexhall Industries Inc., formerly a publicly traded manufacturer of RVs and distributor of buses and coaches. He previously served as president of THOR West, a subsidiary of THOR Industries that manufactures shuttle buses, and as president of BYD Coach and Bus.

Patrick J. Parenti is the SVP Global Sales at DSG subsidiary Vantage Tag Systems. He has nearly 30 years of experience in golf and golf course management. Prior to joining DSG in 2012, Mr. Parenti served for 10 years as SVP at ProLink Systems, a leading global provider of GPS golf-course management systems.

Clint Singer is Director of Engineering at Vantage Tag Systems. He has been a senior developer in the golf industry for more than 20 years and has an extensive background in GPS systems.

Daniel Price is Technical Operations Manager of DSG Global’s European Region, UK, South Africa. In addition to his background in mechanical and electronic engineering, he is an audio engineer, specializing in automotive audio and security. He has also worked with high end electronic security companies in the UK and previously owned an electronic security and CCTV company.

Steven Mueller is Operations Manager at Vantage Tag Systems. He worked in the global pulp and paper market for nine years, facilitating the global movement of thousands of tons of timber products annually. Additionally, he has a successful decades-long track record of managing operations and consulting for a wide range of retail businesses.

DSG Global Inc. (DSGT), closed Thursday’s trading session at $0.2, up 0.368856%, on 348,944 volume with 93 trades. The average volume for the last 3 months is 1.013M and the stock's 52-week low/high is $0.0108/$1.51999998.

Recent News

Kaival Brands Innovations Group Inc. (KAVL)

The QualityStocks Daily Newsletter would like to spotlight Kaival Brands Innovations Group Inc. (KAVL).

Kaival Brands (OTCQB: KAVL), the exclusive global distributor of products manufactured by Bidi Vapor LLC, today announced the appointment of George Chuang, CEO of Lucy Labs Inc., to its board of directors. “We are pleased and honored to welcome George Chuang as an independent director to our board. Additionally, we are excited to announce Mark Thoenes has joined us as interim chief financial officer,” said Niraj Patel, Kaival Brands' chief executive officer. “We look forward to benefiting from George's diverse global background and expertise within the financial sector. We are confident his value will prove indispensable as we work to navigate towards securing international distribution. Mark's role as interim CFO will further bolster our corporate financial team and adds another important layer of experience.” To view the full press release, visit https://ibn.fm/EfI1w

Kaival Brands Innovations Group Inc. (KAVL) is focused on growing and incubating innovative and profitable products into mature, dominant brands. It aims to develop internally, acquire or exclusively distribute these products, helping them grow into market-share leaders by providing superior quality that is recognizable in their individual industries.

Formerly known as Quick Start Holdings Inc., the company changed its name to Kaival Brands Innovations Group Inc. (also known as Kaival Brands) in July 2019. Headquartered in Grant, Florida, the company commenced business operations on March 9, 2020.

Bidi™ Stick – Revolutionizing the Vaping Experience

On March 9, 2020, Kaival Brands entered into a partnership with Bidi Vapor LLC. The latter granted Kaival Brands exclusive global distribution rights for the innovative Bidi™ Stick.

Bidi™ Stick is a completely self-contained disposable product that is tamper-proof and recyclable. The innovative product is made from high-quality components and equipped with a long-lasting battery and class A nicotine. Its product engineering also includes a sensitivity control system, along with a proven mechanism designed to help identify and eliminate counterfeit products.

Available in 11 flavors, the Bidi™ Stick offers a premium vaping experience for adult consumers only. From its packaging design to its marketing strategies, Bidi Vapor makes sure that everything is compliant with government regulations.

On March 31, 2020, Kaival Brands partnered with QuikfillRx Digital as a digital service provider to help promote and commercialize the Bidi™ Stick. As a direct result of the partnership, Kaival Brands received back-to-back orders for the vaping device, totaling approximately $135,000, from sizable national convenience chains.

On September 8, 2020, the company announced that Bidi Vapor had submitted its Premarket Tobacco Product application (PMTA) to the U.S. Food and Drug Administration (FDA) for review. In total, over 285,000 pages of research, studies and surveys were submitted to support the application of Bidi™ Stick’s 11 variants.

“We are confident that, upon review, the FDA will authorize Bidi Vapor’s Bidi™ Stick for continued marketing in the United States,” Niraj Patel, President and CEO of Kaival Brands, stated in a news release (http://nnw.fm/unAyG).

Bidi Vapor is an industry leader in recycling – a position that was furthered through the creation of the Bidi Cares Initiative. The program encourages users to recycle their used Bidi™ Sticks instead of trashing them. As motivation, Bidi Vapor offers a free Bidi™ Stick for every 10 used devices recycled by a consumer. Kaival Brands is the exclusive recycling provider for the initiative.

Partnership Impact and Market Outlook

Bidi Vapor is a related party to Kaival Brands, as it is owned by Kaival Brands CEO Nirajkumar Patel. Patel is also the majority stockholder of Kaival Brands, placing both entities under common control.

The partnership has already had a positive impact on Kaival Brands, helping the company expedite growth, as evidenced by its Q2 financial results. According to Kaival Brands’ consolidated fiscal results for the quarter that ended on April 30, 2020, its revenues grew to approximately $22.5 million from no revenue in the same quarter of 2019. The company also scored a gross profit of $4.2 million for the three-month period. Net income was reported at $2.8 million for the quarter, compared to a net loss of about $4,000 in the second quarter of 2019. The company ended the second quarter of 2020 with a cash balance of $2 million (http://nnw.fm/44sq4).

The positive results are primarily an effect of Bidi™ Stick distribution amid the growing worldwide demand for high-quality vape products, as Patel explained in a news release. “Our focus now is to continue to increase revenues by increasing Bidi Vapor’s market share in the vaping industry,” he added.

Internationally, Kaival Brands has already taken steps to expand distribution of the Bidi™ Stick into Guam, Canada, the European Union, the United Kingdom, Australia and New Zealand.

To this end, the company has set up a market engagement and sales force to reach a higher volume of retail and wholesale customers. It also created a dedicated customer support team to provide high-quality service and an enhanced customer experience.

Kaival Brands is dedicated to developing innovative and viable options for adults who use tobacco and vape products and want a premium experience. The company wants to set higher standards to transform perceptions and elevate consumer experience in the vape and CBD industries, with a goal of increasing market share in the ever-growing vaping industry. In 2019, the reported global market for the vaping industry alone was $12.4 billion. These forecasts indicate a potential CAGR of 23.8% through 2027.

Cancellation of 300 Million Shares of Common Stock

In August 2020, the company canceled 300 million shares of common stock, marking a 52.1 percent reduction in its issued and outstanding shares of common stock (http://nnw.fm/W7s9T). Currently, the company’s outstanding common shares total 277,282,630. The cancelation was done in exchange for three million shares of Series A Preferred Stock. The Series A Preferred Stock cannot be converted before November 2023, barring any event that may trigger early conversion.

According to Patel, this move will benefit all shareholders and help maintain stability of the market pricing of remaining common stock. The overall goal is to increase value for long-term investors.

Management Team

Nirajkumar Patel is the CEO, CFO, President, Treasurer and Director of Kaival Brands and owner of Bidi Vapor LLC. In 2004, Patel received a Bachelor of Science in pharmaceutical sciences from AISSMS College of Pharmacy in Prune, India. He moved to the United States in 2005, and he continued his education at the Florida Institute of Technology, where he graduated in 2009 with a master’s degree in medicinal and pharmaceutical chemistry. He currently holds a Six Sigma Black Belt Certification.

Eric Mosser is the COO, Secretary and Director of Kaival Brands. Mosser attended Arizona State University, where he studied business management. In 2004, he graduated from Rio Salado College with an associate degree in applied science in computer technology.

Kaival Brands Innovations Group Inc. (KAVL), closed Thursday’s trading session at $0.85, up 11.8568%, on 165,079 volume with 84 trades. The average volume for the last 3 months is 149,612 and the stock's 52-week low/high is $0.228300005/$3.65000009.

Recent News

Healthtech Solutions Inc. (OTC: HLTT)

The QualityStocks Daily Newsletter would like to spotlight Healthtech Solutions Inc. (OTC: HLTT).

Healthtech Solutions (OTC: HLTT), an innovative portfolio-model life sciences company focused on building impactful solutions for patients and the healthcare system through its subsidiary companies ranging in stage from preclinical to commercial growth, has named Brad Mathis as its new chief operating officer and Ryan Salomone as a new member of the company’s board of directors. Mathis and Salomone have decades of experience in the healthcare, pharmaceutical and biotech industries, and their appointments broaden the company’s leadership teams. Mathis comes from Argenx Inc., where he most recently served as vice president and general manager of the company’s US Neurology franchise; he also held positions of responsibility at Amgen, Celgene, Biogen and BMS. Mathis has been involved in a number of successful product launches and led multiple cross-functional teams. Salomone brings more than a decade of experience working at Fidelity Institutional Asset Management with a focus on healthcare investing; his most recent role was as a senior healthcare analyst on the small cap team. Salomone also co-founded an asset management firm focused on systematically managed investment strategies, where he serves as the chief investment officer. To view the full press release, visit https://ibn.fm/fsWFS

Healthtech Solutions Inc. (OTC: HLTT), through its Mediscan Inc. subsidiary, created a cloud-based software for ultrasound technology that reconstructs the analog two-dimensional grayscale visual image into a digital three-dimensional, high-definition quantifiable format.

The Mediscan software application dramatically increases the medical professional’s ability to use existing ultrasound devices at the point of care to derive meaningful data-driven clinical evaluations of a patient’s pathology or trauma, facilitate support for treatment options, monitor the patient’s ongoing progress or regress, and document compliance with required protocols and procedures. The Mediscan application also integrates with all popular EMR systems.

Healthtech Solutions Inc. acquired all of Mediscan’s capital stock in a reverse acquisition transaction on November 13, 2020. On November 23, 2020, the shareholders of Healthtech Solutions Inc. consented to a resolution changing its name to Healthtech Solutions Inc.

The company’s operational focus for the immediate future will be on Mediscan’s continuing research and development of imaging, development of other medical solutions, and making strategic investments.

Mediscan Technology

Mediscan software transforms an ultrasound analog 2D grayscale image into a digital 3D HD format. When paired with a portable ultrasound machine, the software application can enable these detailed and quantifiable scans by on-the-scene medical professionals, such primary care physicians, specialists and technical support staff, as well as sports trainers, emergency medical services (EMS) personnel, and technicians in isolation wards and emergency rooms.

Once an image has been captured in 2D, it is converted using a cloud-based software application process – a process that takes approximately one minute. The completed 3D image is viewed on the medical professional’s computer monitor, pad or smartphone at the point of service. This technique can generate 3D medical images of different organs, such as the heart, lungs, tendons, skin and nerves.

This cloud-based software application for ultrasound devices is easy to use anywhere there is an internet connection. The application provides the convenience of point of care ultrasound with the image quality of CT or X-ray and the safety of very expensive MRI technology. For patients, it provides a convenient and comfortable medical experience.

Mediscan has filed two patent applications with the United States Patent and Trademark Office, both for a System Method, Apparatus, and Computer Program Product for Ultrasonic Clinical Decision Support (https://ibn.fm/lpImS).

The technology will initially be available as medical software-as-a-service (SaaS), resulting in cost-efficiency. The SaaS model eliminates the customer’s need for external hardware and software solutions, as well as technical maintenance. The SaaS model is already widely used in the health care industry, most notably for clinical information systems and supply chain management, revenue cycle management and billing. Benefits include increased patient and physician satisfaction, lower operational costs, better workflows and more. Per company data, the Mediscan system is fast and efficient, which could generate a significant cost reduction.

Health and Wellness Applications

Mediscan’s technology has shown success in musculoskeletal (MSK), lung and cardiac imaging, enabling rapid pathology evaluation. Scanning the lung and or the MSK sub-system, the application directly images the target area, saves it as a reference, and then compares it to previous images, helping to determine if the patient is progressing or regressing.

The cardiac application combines imaging with a therapy system that detects and classifies cardiac myopathy conditions via an “entrainment” process similar to that used in treating tachycardia. This application also features a comparison function where the latest imagery is interpreted against previous vetted cardiac images to detect progression or regression.

Mediscan’s technology can also be utilized on the wellness market for diagnostics and support in a wide range of situations, such as sports injuries, physical therapy and dermatological indications.

COVID-19 Applications

COVID-19 causes complications with patients’ cardiovascular and pulmonary systems. Mediscan’s technology could help meet the growing need for advanced diagnostic and monitoring imaging at the point of care.

Portable ultrasounds equipped with Mediscan’s application are a flexible and easy-to-use solution for health care providers to evaluate, triage and diagnose COVID-19 effects on contagious patients in isolation where MRI, CT or PET Scans are not accessible. With this technology, health care providers can easily detect lung lesions or heart muscle shredding, which often appear in patients with COVID-19.

Diagnostic Imaging Market Outlook

With the increasing demand for early diagnosis and a widening scope of clinical applications, any promising technological advancements in the field constitute a significant investment opportunity. The global market is also being driven by technological advances in the diagnostic imaging industry.

As standard ultrasound 2D greyscale images are generally the norm, and 3D imaging typically requires the use of CT, PET, MRI or X-ray technology, Mediscan’s application could have a dramatic impact on the medical imaging industry, meeting the need for imaging equipment and devices that can generate human anatomy data in 3D.

The global market for diagnostic imaging was estimated at approximately $100 billion in 2016 (https://ibn.fm/xtInK) and was expected to grow steadily, creating a promising opportunity for Mediscan to distribute its technology and achieve its mission as a developer and distributor of medical imaging solutions designed for both long-term care and acute and emergency medical services.

Management Team

David Rubin is the Chairman and CEO of Healthtech Solutions Inc. Mr. Rubin has been in the financial services business for over 20 years. Concurrently, he is also the CEO of Capital Stack LLC and CEO of eProdigy Financial LLC. Rubin attended Kingsborough Community College from 1985 to 1988.

Manuel Iglesias is the President and a Director of Healthtech Solutions Inc. Mr. Iglesias has practiced law since 1980, specializing in business law, merger and acquisitions, securities and health care. Mr. Iglesias served as President, CEO and a board member of Hygea Holdings Corp., which provided primary care medical services throughout Florida and Georgia. He served as the National Chairman of the Republican National Lawyers Association in 2019 and 2020. Mr. Igleisias was awarded his MBA degree from the University of Chicago in 1981, a Juris Doctorate from the University of Chicago in 1979, and a BS in Foreign Service from Georgetown University in 1976.

Denis Kleinfeld is a Director of Healthtech Solutions Inc. and General Counsel and a Director of Mediscan Inc. Mr. Kleinfeld has extensive experience in business planning and regulatory compliance. Mr. Kleinfeld is a renowned expert in international tax and estate planning law. Kleinfeld received his Juris Doctorate from the Loyola University of Chicago School of Law in 1970.

Richard F. Parker is the Chief Research Officer of Mediscan Inc. He developed the technology that is the foundation of Mediscan’s business plan. Before he joined Mediscan, Mr. Parker was employed as an engineer and business executive for 37 years. Previously, he was President and Chief Technology Officer of CytoWave LLC. Mr. Parker was awarded a patent for technology that supported a Method and Apparatus for Generating a Therapeutic Magnetic Waveform. During the past 10 years, Mr. Parker has published 14 papers and made numerous presentations focused on magnetic imaging and treatment of sports and equine injuries. He obtained his MSEE degree from the Georgia Institute of Technology in 1971.

Healthtech Solutions Inc. (HLTT), closed Thursday’s trading session at $1.05, up 5%, on 3,377 volume with 8 trades. The average volume for the last 3 months is 6,167 and the stock's 52-week low/high is $0.041499998/$4.00.

Recent News

Golden Triangle Ventures Inc. (OTC: GTVH)

The QualityStocks Daily Newsletter would like to spotlight Golden Triangle Ventures Inc. (GTVH).

  • Golden Triangle Ventures (OTC: GTVH) is making a strong statement about its confidence in the $67-billion U.S. wine industry (https://cnw.fm/d3vnX) with its recent acquisition announcement. In May, the company acquired the Lodge Winery & Olive Oil Co. under the company’s Food & Wine Division, Napa Wine Brands Inc. (https://cnw.fm/TDEUq).
  • Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company pursuing ventures in the health, entertainment and technology industries, has shared a letter from Arron Johnson, CEO of Napa Wine Brands, written to shareholders. The letter includes an update on the company’s Food & Wine Division activities and outlines the division’s corporate strategy. In the letter, Johnson notes that Napa Wine Brands was recently acquired by Golden Triangle Ventures; consequently, the two companies are working to launch many brands and products within Napa Wine Brands. Johnson also noted the company’s acquisition of The Lodge Winery & Olive Oil Co., an established wine brand that produces award-winning wines. Johnson noted that less than half of the wineries in the Northern California wine country have tasting rooms or facilities open to the public, and The Lodge Winery & Olive Oil Company will be one of them. In the letter, Johnson also observes that the company doesn’t own any vineyard but rather buys raw materials from contracted suppliers; that its wine making and bottling facility is currently in Napa Valley; and that its unique outdoorsman’s “niche” opens the door for additional sales and PR through the many outdoor organizations. To view the full press release, visit https://ibn.fm/VyoB9

Golden Triangle Ventures Inc. (OTC: GTVH) is a multifaceted consulting company pursuing ventures in the health, entertainment and technology industries, with many additional projects being developed that provide synergistic values to these divisions. The company aims to purchase, acquire and/or joint venture with established entities that management can help assist and develop into unique opportunities.

Additionally, GTVH provides a professional corporate representation service to different companies in these sectors while consulting on a variety of business development objectives. The goods and services represented are driven by innovators who have passion and commitment to these marketplaces.

The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. The three points of the Golden Triangle exclusively represent these three sectors in which the company aims to do business.

Health Division – Global Health Services

Global Health Services is a wholly owned subsidiary of Golden Triangle Ventures (operating under its Health Division). Dedicated to the promotion of well-being and natural wellness, the company currently does business in the industrial hemp/CBD industry. Additionally, the company has a vision to promote, market and generate sales for a myriad of products and services which include a full retail line of high-end, all-natural health, wellness and beauty products.

To help achieve this vision, Global Health Services is in the process of further developing an extensive online portal that will support the multiple verticals under the company and provide a one-stop-shop for all of the company’s products and services. Moreover, to support overarching business goals, senior management tirelessly works on acquiring and building an array of profitable assets and projects.

Entertainment Division – Lavish Entertainment

Lavish Entertainment (EpicRaves) is a wholly owned subsidiary of Golden Triangle Ventures under its Entertainment Division. Operating out of Las Vegas, Nevada, the company started doing business in 2017 and was established with a vision of becoming a nationally recognized concert production company. The company currently has more than 30,000 national followers and nearly 100 team members who have helped the company successfully organize some of the most exciting Electronic Dance Music concerts in Las Vegas.

Lavish Entertainment is currently doing business as EpicRaves, which will eventually become a wholly owned subsidiary of Lavish Entertainment as the company expands its business into a variety of other forms of entertainment. The company is currently building a unique virtual reality platform to help expand on its live events, and it is working to acquire a 68,000 sq. ft. event center with a vision to develop one of the most advanced event centers in the world.

Technology Division – HyFrontier Technology

HyFrontier Technologies is a wholly owned subsidiary of Golden Triangle Ventures under its Technology Division. The company owns a patent-pending process and device technology called HyGrO, which is a molecular hydrogen and oxygen delivery system for agriculture. Golden Triangle Ventures is assisting the company in commercializing the HyGrO unit for farm and home use in markets across the globe. HyFrontier Technologies has a mission to improve global crop production efficiency by producing hydrogen and oxygen directly in the water stream.

This technology can be used on any species of plant life in nearly any grow medium. Additionally, the system can be retrofitted to wellheads for large-scale agricultural projects, indoor grow operations and small farms or utilized for a multitude of residential home and garden applications. In-house testing has shown evidence that hydrogen is capable of increasing crop yields by up to 25% and, in many circumstances, a much higher amount. Larger root systems and better overall plant health were also observed by watering plants with the HyGrO unit. Universities and multiple third-party testing facilities are currently working to validate the HyGrO technology, and all preliminary results are extremely positive.

To push the development and commercialization of the technology, management is now in the process of moving the company headquarters from Colorado to Florida, which will transition its operations into a 7,800 sq. ft. state-of-the-art manufacturing facility. The company recently executed a three-year lease with an option to purchase the entire 24,000 sq. ft. building, which will help the business in achieving its ultimate goal of commercializing this technology to the world.

Food & Wine Division – Napa Wine Brands

Napa Wine Brands is a wholly owned subsidiary of Golden Triangle Ventures which is a synergistic business with a mission of providing a world-class portfolio of unique brands birthed from Napa Valley and Sonoma Valley in the heart of California’s Wine Country.

The company has a commitment to manufacture and distribute specialty wines, foods and unique items while tapping into an array of hidden markets in the food and beverage industry. With extensive resources and award-winning products, Napa Wine Brands aims to develop some of the most desirable products in today’s market. Originated by some of the most profound experts in Napa Valley, the company’s vision is to broaden the horizon of a traditional food and wine company by creating a platform different than anything seen in the Northern Hemisphere.

Napa Wine Brands has an array of fully developed products and services that provide value to the other divisions under Golden Triangle Ventures. The company is now preparing the launch of several brands, products and services that are market-ready and will immediately turn into cash-positive businesses. Golden Triangle Ventures will provide a full support system and assist management of Napa Wine Brands in growing this company into another fun, exciting and profitable division of Golden Triangle Ventures.

Recent Updates

  • On May 26, 2021, Golden Triangle announced its acquisition of The Lodge Winery & Olive Oil Co. under the company’s Napa Wine Brands subsidiary. The Lodge Winery & Olive Oil Co. is an established wine brand that produces award-winning wines, olive oils and wine vinegars. “Our marketing team is now ready to launch an in-depth program focused on driving our products into big box stores, smaller retail outlets, online platforms and many other avenues,” Steffan Dalsgaard, CEO of Golden Triangle, stated in a news release announcing the acquisition. “We are working directly with [Napa Wine Brands CEO] Arron [Johnson] and his team to grow their bulk inventory and launch all of these products for the world to enjoy.”
  • On May 20, 2021, Golden Triangle announced its entry into a letter of intent to acquire Sonder Fulfillment LLC, a leader in the industrial hemp and CBD space that is dedicated to driving forward the most powerful and efficacious cannabinoid products in the world. “Over the past two years, our operating partners have compiled a team of the best minds in the industrial hemp industry to create a totally vertical operation from seed to shelf,” Joshua Weaver, CEO of Sonder Fulfillment, stated in a news release announcing the LOI. “This acquisition by Golden Triangle Ventures will fully capitalize our operations and allow us to further expand our product lines and enter into new markets across the globe.”
  • On May 19, 2021, Golden Triangle announced the execution of a formal agreement with Robert “Bo” DuBose to purchase the remaining 49% of HyFrontier Technologies Inc., giving Golden Triangle 100% ownership of the technology company. “This acquisition has been something that Bo and I have been working towards for quite some time and we are both incredibly happy to have this executed,” Dalsgaard stated in a news release announcing the acquisition. “We knew that completing this agreement would show the world that we are both fully committed to our shareholders and the brilliant future of this revolutionary company.”
  • On May 12, 2021, Golden Triangle announced its acquisition of a top tier, professional sound system and formed a partnership with SuperKollider Sound LLC to provide a strategic benefit to the company’s entertainment division under Lavish Entertainment Inc. “We are very excited to acquire this unbelievable sound system,” Dalsgaard stated in a news release announcing the acquisition. “Hennessey Sound Design has always been one of my favorite systems on the market, and the team at SuperKollider Sound are true professionals in this space.”

Management Team

Steffan Dalsgaard is the Founder & Executive Chairman of Golden Triangle. He has a background in business development, with over a decade of experience representing and consulting with dozens of private and public companies. Mr. Dalsgaard consults with companies on all of their corporate objectives while providing a professional and corporate face to their organizations. He has built a strong reputation in the public relations industry and has a mission to work with emerging growth companies that are positioned to become significant businesses in their respective fields.

Robert DuBose is the company’s Chief Innovations Officer & Director and the CEO of HyFrontier Technologies Inc. Mr. DuBose is responsible for the success of the HyGrO product in the agricultural market. His experience in the design and production of hydrogen equipment goes back more than a decade, including PEMFC technologies since 2009 with his company, Aquafuel Inc. Mr. DuBose was raised in the farming and machine shop business, where he learned firsthand how much work and love goes into a successful crop, as well as how elements, which are out of the farmers control, can have adverse effects on finances. His belief that being able to deliver a solution to increase growth, yield, health, stamina of crops and profitability for farmers would be a win-win for all led him to create the HyGrO product.

Stuart Seim is the Chief Development Officer & Director of Golden Triangle. He began his career as an associate professor at the University of Manitoba in the field of outdoor and environmental education after receiving his master’s degree and completing advanced educational studies. Coming from a family with an extensive financial background, Mr. Seim became a stockbroker for major regional financial firm Robert W. Baird. In a short time, he became the Branch Manager for Baird in Minneapolis, Minnesota, while also serving as a Managing Director for Baird. During this time, Mr. Seim also served on the board of an industrial hearing company, which he helped to launch as a new company (The TK Group). Mr. Seim currently resides in Colorado, where he is an advisor to several organizations.

Golden Triangle Ventures Inc. (GTVH), closed Thursday’s trading session at $0.15394, up 2.6267%, on 219,532 volume with 56 trades. The average volume for the last 3 months is 662,163 and the stock's 52-week low/high is $0.018999999/$0.949899971.

Recent News

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF)

The QualityStocks Daily Newsletter would like to spotlight Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF).

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is finalizing the design of its i/Blue Imaging System(TM), with manufacturing expected to be completed in 2022. The system is an innovative technology designed to significantly improve surgeons’ ability to visualize cancerous cells and enable more accurate bladder cancer resection. It solves challenges associated with using blue and white light cystoscopies, which require surgeons to switch back and forth between images and rely on memory to resect. To view the full article, visit: https://ibn.fm/KF7vv

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures. Its initial focus is on bladder cancer.

The company’s first product is the i/Blue Imaging™ System, based on advanced optics and light sensors and employing patented ultrasensitive imaging technology. Imagin Medical believes the system can significantly improve surgeons’ ability to visualize and remove cancer cells.

Founded in 2016 and headquartered in Boston, Massachusetts, the company works to enhance its market potential by expanding its technology to multiple endoscopic indications, such as laparoscopic, colorectal and thoracic procedures, accommodating multiple contrast agents and illumination sources.

i/Blue Imaging™ System

The conventional method used for visualizing bladder cancer during surgery is an endoscopic procedure called a cystoscopy. This procedure uses white light to illuminate the bladder. White light has been used for decades and is the standard for more than 90% of the market. Blue light cystoscopy uses blue-filtered white light, which addresses the limitations of white light (such as detecting flat tumors and the fine edges that may result in cancerous cells being left behind during removal).

Blue light uses a contrast agent that causes cancer cells to fluoresce when illuminated. Surgeons are then able to more effectively visualize and resect the margins of bladder tumors to reduce the risk of recurrence. Notably, the use of the white light is still necessary during a blue-light procedure so that the surgeon can orient their position within the bladder.

Imagin Medical’s i/Blue Imaging System addresses the limitations of both white and blue light cystoscopies. The i/Blue System combines the white and blue light with an FDA-approved imaging agent and simultaneously displays side-by-side images in real-time, without the necessity to switch back and forth between the two images.

The i/Blue Imaging System is unlike other methods available on the market today. It is external to the body and can attach to almost any endoscope model currently in use. This way, hospitals adopting Imagin Medical’s technology have the ability to use their current endoscopes without the need to purchase new equipment.

Bladder Cancer Prevalence

The company’s initial focus is bladder cancer, which is the sixth most prevalent form of cancer in the United States. In 2020, the number of new bladder cancer cases is expected to total 81,400, accounting for 4.5 percent of all new cancers diagnosed. The death rate in 2020 for cancer deaths associated with the bladder is forecast at 17,980, or 3% of all cancer-related deaths (https://ibn.fm/qLi3l).

Bladder cancer also has one of the highest recurrence rates among all forms of cancer, leaving about 600,000 people in fear that their cancer will return, according to Imagin Medical. The company is committed to addressing this issue, and i/Blue demonstrations have indicated that the use of both white and blue light can enhance accuracy of detection and removal of cancer cells, potentially lowering recurrence rates.

Based on Verified Market Research, the global bladder cancer research market was valued at $3.43 billion in 2018. It is estimated to grow with a CAGR of 4.03% through 2026, resulting in a projected $4.71 billion market (https://ibn.fm/rI7G6).

Management Team

E. James Hutchens is the Chief Executive Officer of Imagin Medical Inc. He is a proven entrepreneur with over 30 years of experience in management in the medical technology industry. Hutchens served as a managing partner with Origin Partners, a $55 million early-stage venture capital fund. He was also the founder and CEO of both Microsurge Inc. (a venture-backed minimally invasive surgical company) and Choice Therapeutics (an advanced wound-care company). He is a former member of the Board of Directors of the Brigham and Women’s and Faulkner hospitals. Hutchins holds a BS in Business Administration from Boston University.

John Vacha is the company’s Chief Financial Officer. He has 20 years of experience in the health care industry. Prior to Medtronic’s acquisition of Intact Medical Corp. in 2017, Vacha was the company’s President, CEO and a board member for seven years. He is a licensed CPA in Massachusetts. Vacha has an MBA and an MS in Accounting from Northeastern University in Boston. He is also a serving member of the Board of Directors at the South Boston Health Center. He currently has two patents in electrosurgical instrumentation.

Michael G. Vergano is the Director of Operations of Imagin Medical. He has been the President of The Harvest Group Inc. since 1998, where he has provided consultant services for startups and major corporations. Vergano has over 30 years of experience in the medical device industry. He has held management positions at Microsurge Inc., Ciba Corning Diagnostics and Boston Scientific Corp. He is currently the holder of 11 medical device patents and holds a BS in Mechanical Engineering from Tufts University.

Pam Papineau is the company’s Director of Regulatory Affairs. She has over 30 years of experience in quality and regulatory affairs with Boston Scientific, Baxter and Cogentix. She has served as a consultant on various devices including imaging, endoscopy, orthopedic, GI/GU and cardiovascular applications. Papineau has successfully prepared dozens of FDA pre-market and EU submissions to support CE marking of a broad spectrum of medical devices. She is an ASQ Certified Quality Engineer, a Certified Biomedical Auditor, a Certified Quality Auditor and an ISO 13485:2016 Lead Auditor, and she is certified by the Regulatory Affairs Professional Society – U.S., EU and Canada. Papineau works with the company’s legal counsel to prepare pre-submission meetings with the FDA and activities through the regulatory approval process.

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF), closed Thursday’s trading session at $0.4683, up 11.5%, on 2,470 volume with 3 trades. The average volume for the last 3 months is 6,706 and the stock's 52-week low/high is $0.200000002/$1.16999995.

Recent News

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

  • Pressure BioSciences (OTCQB: PBIO) (“PBI”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform technology solutions to the worldwide biotechnology and other industries, today announced the successful application of its Ultra Shear Technology(TM) (“UST(TM)”) platform. According to the update, the novel UST platform was used for the development of more potent formulations of wide-ranging nutraceuticals of high therapeutic value, allowing for more controlled dosing and opportunities for lower cost solutions for both manufacturers and consumers. Specifically, PBI reported breakthrough results in processing one of the most powerful antioxidants known to science, astaxanthin ("AsX"), in extremely fine and uniform, monodisperse nanoemulsions of oil in water. These results are critically important for fast and efficient absorption by the water-based biochemistry of humans and animals. To view the full press release, visit https://ibn.fm/ffrin.
  • Also today, the company was highlighted in a publication from Financialnewsmedia.com, examining how a report from Market Research Future said that because Astaxanthin is said to have many health values it is projected that the Astaxanthin Market is expected to register a CAGR of 7.7% to reach USD 1,206.52 Million by 2026. “It’s been linked to heart health, endurance, healthier skin, joint pain and may even be applied in future cancer treatment. As a result of this, astaxanthin finds usages in more than a few industries, counting food and beverages, pharmaceuticals, animal feed, and nutraceuticals.”  

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions — all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Thursday’s trading session at $2.42, up 11.5207%, on 66,466 volume with 131 trades. The average volume for the last 3 months is 9,885 and the stock's 52-week low/high is $1.28999996/$3.00.

Recent News

Green Hygienics Holdings Inc. (OTCQB: GRYN)

The QualityStocks Daily Newsletter would like to spotlight Green Hygienics Holdings Inc. (OTCQB: GRYN).

Green Hygienics Holdings (OTCQB: GRYN) today issued an invitation to investors to attend its virtual shareholders update meeting at 1:15 p.m. Pacific Time on July 12, 2021. Green Hygienics CEO Ron Loudoun will host the call and provide an overview of recent announcements, continued improvements to the company's balance sheet, an overview of the revenue-focused build out of sales and distribution, and GRYN’s 2021 fiscal strategy. Interested parties may join the call by dialing 760-501-8900 and entering PIN: 64365. Green Hygienics’ corporate mission remains to adhere to the highest standards of operations in consistently delivering safe and premium quality products to its primary target market, the medical, nutraceutical and pharmaceutical industries. The company also intends to leverage these same strategic advantages in partnerships with CPG (consumer-packaged-goods) companies. To view the full press release, visit https://ibn.fm/ZMOqH

Green Hygienics Holdings Inc. (OTCQB: GRYN) is a California-based innovative technology-driven enterprise focused on the high standard cultivation and processing of industrial hemp and manufacturing of pharmaceutical-grade bioactive cannabinoids.

The company aims to be a leader in compliance and capabilities in the hemp and cannabinoid supply marketplace. By leveraging state of the art technologies, the company intends to open up a whole new world of novel cannabinoids and targeted bio-delivery technologies never before explored, solving the issues of stability, pharmacokinetics, biological tissue penetration and bioavailability.

Dedicated to creating the hemp industry’s safest and finest quality products, the company will be uniquely positioned to deliver product efficacy and supply chain solutions to consumers, as well as to leverage these within its own products and brand portfolio.

USDA Organic Certification and FDA Registration

On August 26, 2020, Green Hygienics registered with the U.S. Food and Drug Administration pursuant to the Federal Food Drug and Cosmetic Act, as amended by the Bioterrorism Act of 2002. This registration strengthens the company’s core mission to provide product efficacy to the pharmaceutical industry and consumers alike.

On September 30, 2020, Green Hygienics was granted USDA Organic Certification (7 CFR Part 205) for the cultivation and post-harvest processing of industrial hemp by the California Certified Organic Farmers for its Sol Valley Ranch property. This certification further enables the company to supply certified organic hemp products to national and international markets.

Market Opportunity

Green Hygienics is focused on finding, acquiring and developing strategically positioned businesses, as well as the best innovations within the hemp industry – a fast-progressing market with remarkable opportunities for growth. The industrial hemp market is expected to reach $5.33 billion in 2020 and is projected to rise to $15.26 billion by 2027, achieving a CAGR of 15.8%, per Grand View Research.

Capital Structure

GRYN has less than 42 million shares outstanding, fully diluted. The company has just 7.2 million common shares in float and boasts a balance sheet with no toxic debt or overhang.

Key Management

Dr. Levan Darjania serves as the company’s Chief Science Officer. Darjania has over 26 years of experience in biotechnology and pharmaceutical drug development. His research and development experience has led him to develop many in-house and collaborative R&D programs over the course of his career.

Kyle MacKinnon serves as GRYN’s Chief Operating Officer. He has extensive knowledge in cannabis processing and was previously the Business Development Manager of Advanced Extraction Systems Inc., a leader in CO2 Supercritical Fluid Extraction. MacKinnon brings over 20 years of sales and management experience to the company.

Ronald Loudoun is the President, CEO, Secretary and Director of Green Hygienics. He received an undergraduate business degree from the British Columbia Institute of Technology. Before joining Green Hygienics, he was the founder and a director of renewable energy firm Archer CleanTech Inc.

Jerry Halamuda is the Senior Vice President of Business Development of the company’s Agriculture Division. He has an extensive career working in the agriculture and horticulture industry. Halamuda has founded, managed and operated multiple successful companies, including Color Spot Nurseries.

John Gildea is GRYN’s Senior Vice President of Corporate Development. He has over 20 years of experience working within the private and public markets. His expertise includes negotiating and structuring private and public financing and mergers. During the course of his work, Gildea has established trusted relationships with a network of equity and capital partners.

Green Hygienics Holdings Inc. (OTCQB: GRYN), closed Thursday’s trading session at $2.17, up 0.462963%, on 19,320 volume with 34 trades. The average volume for the last 3 months is 63,290 and the stock's 52-week low/high is $0.400000005/$2.33999991.

Recent News

Healthy Extracts Inc. (HYEX)

The QualityStocks Daily Newsletter would like to spotlight Healthy Extracts Inc. (HYEX).

A study conducted by researchers from the Arizona State University found that a long-term choline dietary regimen could possibly prevent Alzheimer’s disease. Choline is a nutrient that can be used as a dietary supplement and is found in some foods. Ramon Velazquez, the study’s lead author, and his fellow researchers at the university’s Neurodegenerative Disease Research Center, investigated whether choline could reduce Alzheimer’s effects. The study, which was carried out in 2019, discovered transgenerational benefits of Alzheimer’s disease-like symptoms in mice whose mothers were given choline. This research is an indication that companies that are operating in the nutraceuticals market targeting heart and brain health, such as Healthy Extracts Inc. (OTCQB: HYEX), may have a big contribution to make in helping people prevent or delay the onset of some of the degenerative diseases afflicting older people.

Healthy Extracts Inc. (HYEX) Healthy Extracts Inc. (HYEX), through its growing portfolio of wholly owned subsidiaries, is engaged in the proprietary research and development of natural plant-based formulations, sales, and distribution of cardiovascular and neuro products. The company’s focus is to advance its market positions in the broader health industry through the unique assets and operations of its science-based BergaMet North America and Ultimate Brain Nutrients (“UBN”) subsidiaries and to offer better lifestyles through superior health technology.

BergaMet North America

BergaMet NA is engaged in the sale and distribution of a full line of proprietary product formulations derived from the rare Citrus Bergamot SuperFruit™ called “bergamot.” Bergamot is native to Southern Italy and is naturally sourced and uniquely loaded with various antioxidant polyphenols. Thanks to this composition, bergamot supports and promotes overall wellness specific to cholesterol, cardiovascular and metabolic health with no known side effects.

BergaMet NA is the only Citrus Bergamot SuperFruit™ heart health supplement backed by 17 clinical studies. The BergaMet brand supplement boasts the highest quality and concentration of polyphenols and flavonoids available anywhere in the world. It is also the only bergamot supplement approved by the prestigious Accademia del Bergamotto of Italy. BergaMet NA is the only company authorized to manufacture, distribute and sell these products in the United States, Canada and Mexico.

Consumers are including the Citrus Bergamot SuperFruit™ in their everyday personal health programs. The clinically proven antioxidant provides benefits to tens of thousands of people daily.

The company’s line of products can be found at www.bergametna.com, through Amazon, other online retailers and in doctors’ offices throughout the United States.

The BergaMet Advantage

BergaMet has been studied in 17 published clinical trials which reported results of lower LDL cholesterol, higher HDL cholesterol, lower triglycerides, lower blood pressure, lower blood glucose, increased arterial function, improved liver function and is effective as a complement to statin use.

Cardiovascular disease is the number one cause of death in the U.S. and worldwide, claiming nearly 18 million lives each year accounting for 31% of all global deaths. In the U.S., statins are one of the most commonly prescribed medicines for cardiovascular disease. The Centers for Disease Control estimates that 28% of American women and men over the age of 40 take a statin to lower the amount of cholesterol in the blood.

Taking aim at this market for cardiovascular care, BergaMet NA continues to advance the awareness of its medical-grade supplements and separate its formulation from competitors.

BergaMet NA products contain 47% BPF (bergamot polyphenolic fraction), while its closest competitors have only 38%. The company’s increased dosages (600-675mg vs 500mg) and 47% BPF are clinically proven to be more effective in improving heart health and metabolic syndrome.

BergaMet Citrus Bergamot SuperFruit™ supplements:

  • Support healthy immune systems with powerful antioxidants and proprietary formulations.
  • Reduce cholesterol and support healthy glucose and blood pressure levels.
  • Are fully organic, vegan-friendly and dairy, gluten, soy and GMO-free.
  • Contain five key unique flavonoids that make up the most powerful 47% BPF (bergamot polyphenolic fraction) in the world, providing superior results compared to their competitors.
  • Have been clinically shown to increase arterial elasticity while reducing arterial and muscle inflammation.

Ultimate Brain Nutrients

Healthy Extracts’ Ultimate Brain Nutrients (“UBN”) subsidiary is a science-based company that develops unique, plant-based superior health technology neuro-products that improve brain health, including memory, cognition, focus and neuro-energy.

UBN’s KETONOMICS® proprietary formulations – targeting brain activity, focus, headache and cognitive behavior — provide multiple intellectual property license opportunities for monetizing the company’s portfolio.

License opportunities include multiple beverage formats, individual products, proprietary mixtures and other food platforms.

UBN has five unique formulation patents – one issued and four pending – targeting brain activity, focus, headache and cognitive behavior.

The UBN Advantage

UBN’s all-natural, sugar-free and caffeine-free proprietary formulations are the result of 20 years of scientific research and are positioned to provide consumer neuro-products that are natural brain solutions. UBN has filed for approval to the U.S. Food and Drug Administration (FDA) to make a Qualified Health Claim for its migraine formulation, tapping into consumer demands for healthy beverages that contribute to brain health, overall well-being and performance.

Over 50 million Americans consume unhealthy energy shots and drinks each day, while the neuro/energy market generates over $10 billion per year in revenue. Within this growing market, UBN is advancing its position to meet rising consumer demand for healthy, science-based options. The company’s KETONOMICS® proprietary formulations have been proven to naturally elevate brain energy and function, including memory, cognition and focus.

UBN’s KETONOMICS® supplementation has also been studied in sports physiology, with specific regard to its potential benefits for competitive performance and endurance.

Healthy Extracts Executive Team

Kevin “Duke” Pitts, Director, President and Chief Operating Officer

  • Started and built from the ground up two multi-million-dollar businesses, one of which grew into a Top 100 retailers in the U.S.
  • Unique management skills led to the development of successful teams for 35 years
  • Pioneered direct marketing for a Fortune 200 company, creating a 20% increase in targeted incremental sales
  • Founded Einstein’s Hemp, which developed and brought to market one of the only odorless and tasteless water-soluble CBD products in the world
  • Developed and implemented digital/guerrilla marketing strategies for public and private companies focused on long-term brand position and acquisition efforts
  • Specialized in customer relationship management (CRM) tools for creating the best customer experiences
  • Worked in publicly traded industries for 10 years, overseeing up to $20 million in annual marketing budgets

William “Bill” Bossung, Director, Chief Financial Officer

  • 35 years of diverse experience in corporate finance, insurance and accounting
  • 20 years of experience with IPOs focusing on audits, FINRA and SEC regulations
  • Specializes in the formation of capital raising over $100 million, recently raising $12 million for Splash Beverage
  • Specializes in upgrading penny stocks companies to the NYSE or Nasdaq
  • Involved in 30+ companies transitioning from private to public identities
  • Founded several companies, including BCF Technology Inc., which sold to Vertafore; managing partner at Bishop Equity Partners LLC; director at Splash Beverage Group; and director of finance at Chadmoore Wireless, where he licensed channels to Nextel for $162 million

Bill Croyle, Director, Private Investor and Accomplished Senior Executive

  • More than 40 years of success in the IT, energy, manufacturing, telecommunications, venture capital and finance industries
  • Broad expertise includes negotiating mergers and acquisitions, as well as service and delivery contracts
  • Formerly was a founder, owner or executive of EnTX Group; Impact Legacy Partners; FB Oilfield Special Tools; and Western Energy Advisors

Dr. Gerald Haase, Chief Medical Officer

  • Clinical professor of surgery at the University of Colorado, School of Medicine
  • Actively involved in medical research and clinical trials for 35 years
  • Received U-10 grant funding from the National Institutes of Health cooperative group clinical trials program, as well as U.S. Congressional funding for Cooperative Research and Development Agreements with the Department of Defense and NASA
  • Was chairman of the Department of Pediatric Surgery at Children’s Hospital Colorado; consultant surgeon to the Department of the Army; vice-chairman of the Children’s Cancer Group, a cooperative research consortium of the National Cancer Institute; on the National Board of Directors of the American Cancer Society; a senior member of the Commission on Cancer of the American College of Surgeons; and a member of the editorial board of The Annals of Surgical Oncology
  • Has published 180 scientific papers and is the inventor or co-inventor of 12 issued U.S. patents for micronutrient and phytonutrient therapy, with five pending patents
  • Recipient of clinical research grants and contracts funded at a several million-dollar cumulative level
  • Is an editorial reviewer for medical journals and a member of numerous professional societies, including the American Association for Cancer Research, International College of Surgeons, American Academy of Pediatrics, New York Academy of Sciences and American College of Physician Executives

Healthy Extracts Inc. (HYEX), closed Thursday’s trading session at $0.06, off by 21.0526%, on 6,500 volume with 2 trades. The average volume for the last 3 months is 15,402 and the stock's 52-week low/high is $0.052000001/$0.100000001.

Recent News

Vivos Therapeutics Inc. (NASDAQ: VVOS)

The QualityStocks Daily Newsletter would like to spotlight Vivos Therapeutics Inc. (NASDAQ: VVOS).

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, has been a trailblazer in diagnosing and treating mild-to-moderate obstructive sleep apnea (“OSA”). Years of research have culminated in its main product, the Vivos System, which has been instrumental in treating OSA among adults. In his new book, Pneumopedics and Craniofacial Epigenetics, Vivos Therapeutic’s founder and Chief Medical Officer Dr. G. Dave Singh shares the process behind Vivos System’s innovation and the scientific and biological foundation of the product. To view the full article, visit: https://ibn.fm/Gemlv

Headquartered in Denver, Colorado, Vivos Therapeutics Inc. (NASDAQ: VVOS) is an emerging global leader in the treatment of mild-to-moderate obstructive sleep apnea (OSA), a debilitating condition affecting nearly 1 billion people worldwide. The company utilizes proprietary, ground-breaking technology, a proven go-to-market strategy, and a powerful executive team dedicated to changing the face of health care by helping people of all ages properly breathe and sleep.

At the core of Vivos’ mission to rid the world of mild-to-moderate OSA is the Vivos System®, a revolutionary clinical breakthrough in the treatment of mild-to-moderate sleep apnea often caused by craniofacial anatomy development. The Vivos System® multidisciplinary treatment protocol involves collaboration between physicians, specially-trained dentists who have completed advanced training in craniofacial sleep medicine, and other ancillary health care providers.

In support of its growth strategy, Vivos has established contract manufacturing facilities in the U.S., Canada and Asia.

Market & Technology Overview

Craniofacial developmental deficiencies, such as underdeveloped upper and lower jaws, are among the leading causes of OSA. According to a 2019 analysis from researchers at the University of California, San Diego, an estimated 81 million adults in North and South America suffer from moderate to severe OSA. The United States has the highest amount of these patients, with approximately 54 million adults affected, according to the report.

Registered with the FDA as a Specification Developer, Vivos develops and markets a number of oral appliances. Its technology represents the first non-surgical, non-invasive and cost-effective treatment for the estimated hundreds of millions of people globally who suffer from mild-to-moderate OSA.

Vivos integrates its specially designed, customized appliances into a patient-specific, multi-disciplinary clinical protocol, giving trained dental and medical providers the tools and roadmap needed to address certain craniofacial conditions that studies have shown to be associated with sleep-disordered breathing—including mild-to-moderate OSA.

The system’s treatment protocol involves collaboration between physicians, specially trained dentists who have received advanced training in craniofacial sleep medicine, and additional health care providers. Vivos-trained clinicians can be found in almost every major city in the U.S. and in many countries throughout the world. The company’s oral appliances have shown to be effective in over 15,000 patients successfully treated worldwide by approximately 1,200 trained dentists.

A New Paradigm in Sleep Medicine

Vivos’ proprietary system poses the potential to be the biggest breakthrough in the treatment of mild-to-moderate OSA since CPAP.

The Vivos System has been specifically designed to promote the proper growth and development of the hard and soft tissues surrounding and comprising the oral cavity, nasal cavity, upper and lower jaws, and other tissues which together form and shape the upper airway. As these areas develop more fully using the Vivos System, a patient’s airway typically widens and expands, enabling them to breathe properly through their nose. With a more open and less obstructed airway, and easier nocturnal breathing, the symptoms of SDB tend to diminish over time, and patients often report they no longer suffer from the adverse effects of SDB or OSA.

Use of the Vivos System is variable and case dependent, but typically recommended to be worn daily for 12 to 16 hours starting in the early evening and continuing overnight. The total treatment time typically ranges from 12 to 24 months, with 18 months being the approximate mean treatment time.

Biomimetic Oral Appliance

Vivos Therapeutics believes that the Vivos System technology represents the first non-surgical, non-invasive and cost-effective treatment for people with mild-to-moderate OSA.

Combining technologies and protocols that can alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and can significantly reduce symptoms and conditions associated with mild-to-moderate OSA.

The Vivos System treatment is typically less than $10,000 and is often reimbursable by medical insurance as an out-of-network benefit.

A potentially serious medical problem with an alternative treatment therapy available in the dental office.

Hard and soft tissues of the craniofacial complex can be non-surgically enhanced using the proprietary Vivos® System devices and clinical protocols.

Leadership

R. Kirk Huntsman – CEO, Director
With experience in strategic development, technology acquisition and product planning, key talent recruitment, and target market prioritization, Huntsman brings a broad vision paired with leadership and strategic planning skills. He has significant start-up experience in a diverse range of market sectors, including medical devices, dental management, dental practice valuations and transitions, multi-location retail, financial and capital formation, consulting, outsourced services, imports and exports (China), medical services, and software and technology.

Dr. Dave Singh – Founder, Director
A doctor three times over in dental medicine, craniofacial development, and orthodontics, Dr. Singh was educated primarily in England and has lectured in North America, Europe, Asia, and Africa. The Global Summits Institute recently named Dr. Singh as one of the Top 100 Doctors in Dentistry.

Vivos Therapeutics Inc. (NASDAQ: VVOS), closed Thursday’s trading session at $4.79, off by 3.2323%, on 44,289 volume with 289 trades. The average volume for the last 3 months is 190,956 and the stock's 52-week low/high is $4.76000022/$14.4099998.

Recent News

Petroteq Energy Inc. (TSXV: PQE) (PQEFF)

The QualityStocks Daily Newsletter would like to spotlight Petroteq Energy Inc. (TSXV: PQE) (PQEFF).

Petroteq Energy Inc. ("Petroteq" or the "Company") ‎‎(TSXV:PQE)(‎OTC PINK:PQEFF)(FSE:PQCF), an integrated oil ‎company focused on the development and implementation of its proprietary oil-‎extraction and remediation technologies, announces its intention to complete debt conversion transactions with two arm's length lenders pursuant to which the Company will issue an aggregate of 2,333,176 common shares of the Company at a deemed price of US$0.094 per share in satisfaction of US$219,318.33, representing certain accrued and unpaid interest under previously issued convertible debentures. In addition, the Company intends to complete debt conversion transactions with its four directors, and one former director, pursuant to which it will issue an aggregate of 862,456 common shares at a deemed price of US$0.094 per share in satisfaction of US$81,071.30 of accrued and unpaid director fees owed to such directors to June 30, 2021. The Company (with the creditors' consent) determined to satisfy the foregoing indebtedness with common shares in order to ‎‎preserve the ‎Company's cash for use on its extraction technology in Asphalt Ridge, Utah, and for working ‎capital.‎

Petroteq Energy Inc. (TSXV: PQE) (PQEFF) is a Canadian-registered, publicly traded company engaged in the development and implementation of proprietary technologies for the environmentally safe extraction of heavy oils from oil sands, oil shale deposits and shallow oil deposits. The company is focused on oil sands exploration and production on mineral leases in Vernal, Utah, and in expanding production capacity at its Asphalt Ridge heavy oil extraction facility in Utah.

Petroteq Energy’s patent-pending application is a closed-loop, solvent-based process, which results in significantly lower per-barrel production costs than those incurred with traditional hot water-based oil sands extraction technologies. This green technology utilizes a small, modular footprint, produces no greenhouse gases, requires no high temperatures, leaves only clean dry sand, and could be deployed to unlock heavy oil deposits located around the world.

The Company’s Asphalt Ridge mineral lease on 2,500-plus acres in northeastern Utah features a large contingent oil sands resource base with an estimated 87 million barrels of oil equivalent. In 2015, the company produced 10,000 barrels of oil from the Utah location and plans to increase production are underway. Utah holds over 32 billion barrels of undeveloped oil sands resources, which are also known as “oil-wet” deposits containing a mixture of sand and a dense, extremely viscous form of petroleum referred to as bitumen or tar. A recent upswing in developing domestic energy sources has intensified interest in technological advances such as Petroteq’s Clean Oil Recovery Technology (CORT) System.

The Company continues to evaluate the development of other medium to heavy oil exploration, production and recovery projects on a global basis through a variety of structured agreements. These opportunities or other arrangements with private and governmental entities that utilize Petroteq Energy’s proprietary licensed technologies are expected to generate a significant return on investment.

The Company’s management team, board of directors and officers form an invaluable cross-section of industry leaders with extensive experience ranging from chemical engineering and solvent research, business development, international project management, entrepreneurial achievements, and senior management for global energy companies in North America and the Middle East. This impressive knowledge base covers both conventional and unconventional oil and gas projects and production, both in upstream and downstream industry sectors.

Petroteq Energy is also participating in a blockchain initiative aimed at solving the global transaction needs of the oil and gas industry through the development of PetroBLOQ. PetroBLOQ recently joined the Enterprise Ethereum Alliance (“EEA”), the world’s largest open-source blockchain initiative. Membership with the 200-member EEA represents a wide variety of industries and offers 14 industry-focused, member-driven working groups.

“Joining this community of forward-looking enterprises and blockchain innovators is an important step for PetroBLOQ as we develop transformative solutions for the oil and gas industry,” said Petroteq Energy Chairman Alex Blyumkin.

In addition, Petroteq has joined the American Petroleum Institute (API). The API is the only national trade association representing all facets of the oil and natural gas industry, promoting safety across the industry globally and influencing public policy in support of a strong, viable oil and natural gas industry.

“API has led the development of operating standards for our industry, and we look forward to contributing our experience with oilfield technologies in addition to introducing our PetroBLOQ platform to its members throughout the supply chain,” Blyumkin previously stated.

Petroteq Energy Inc. (PQEFF), closed Thursday’s trading session at $0.13725, up 7.2266%, on 2,543,267 volume with 380 trades. The average volume for the last 3 months is 3.499M and the stock's 52-week low/high is $0.017999999/$0.249500006.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX).

Lexaria Bioscience (NASDAQ: LEXX) (CSE: LXX) released a status report on six of its studies in the 2021 applied research and development (“R&D”) program. The program mainly involves studies using DehydraTECH(TM) 2.0 formulations, with different market areas of applications including oral nicotine, NSAIDs, antivirals, and hypertension.

Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 19 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Thursday’s trading session at $6.95, off by 0.714286%, on 35,528 volume with 296 trades. The average volume for the last 3 months is 962,601 and the stock's 52-week low/high is $3.97510004/$9.46000003.

Recent News

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT)

The QualityStocks Daily Newsletter would like to spotlight XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT).

Researchers from the University of California-Davis have developed a synthetic version of ibogaine, a psychedelic drug that is nonhallucinogenic. The synthetic compound has the potential to treat various psychiatric disorders, including depression and addiction. The researchers’ findings were reported in the “Nature” journal. David Olson, an assistant professor of chemistry at the institution who was also the senior author of the paper, stated that while psychedelic drugs were powerful substances that affected the brain, it was a shame that very little was known about them. What is known is that ibogaine is extracted from the Tabernanthe iboga plant. Many other companies such as XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are also at work developing their own therapeutic formulations from different psychedelics, so it may not be long before any number of these novel therapies are approved for use by patients suffering from different ailments and mental health conditions.

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. This includes products that are being readied for commercialization within the coming weeks, such as a rapid COVID-19 PCR test kit that reduces turnaround times to less than 30 minutes.

The company has research and development operations in North America and Europe and an operational focus in Germany. Its regulatory approval and commercialization focus is currently on products for the European market.

XPhyto was founded in 2017 and is headquartered in Vancouver, British Columbia.

Business Strategy & Milestones for 2021

On January 18, 2021, XPhyto issued a news release detailing its business strategy for the coming year. The company noted that it is “on the cusp of transformational change as product development programs advance from the laboratory to the clinic.” In addition to continuing to leverage its scientific expertise and operations in North America and Europe for product development and optimization, XPhyto intends to pursue growth through the commercialization of existing products and adherence to a focused investment strategy targeting impact-driven innovation with “the potential for extreme value creation.”

In particular, XPhyto is well positioned to execute on opportunities across its current business divisions, including:

  • Commercialization of infectious disease diagnostics
  • Clinical validation of transdermal and sublingual drug formulations
  • Continued investment and development in psychedelic medicine

“2020 was a very productive year for XPhyto. We made significant progress in all areas of our business,” Hugh Rogers, CEO & Director of XPhyto, stated in the update. “We have ambitious milestones for 2021 with multiple product launches on the horizon, multiple clinical drug programs underway, and an aggressive commitment to psychedelic medicine. I am extremely confident that our team can execute on the company’s business plan for 2021.”

Infectious Disease Diagnostics

XPhyto’s lead diagnostic product, secured through an exclusive global commercialization agreement with 3a-diagnostics GmbH (“3a”), is a rapid and highly portable PCR diagnostic test. Notably, PCR testing “has emerged as the only internationally recognized standard for COVID-19 testing” and is expected to play a key role in facilitating the recovery of the domestic and international travel industries, among others.

Successful validation of the PCR system was achieved in Q4 2020, and XPhyto has expressed confidence that it will achieve European commercial (CE-IVD) approval in Q1 2021. In preparation for this milestone and an anticipated Q1 product launch, the company is currently in discussion with manufacturing and distribution partners in Europe and the Middle East.

In addition to COVID-19 products, XPhyto and partner 3a are developing and commercializing a portfolio of low-cost oral biosensors. The company’s lead biosensor product is an oral health screening test for the detection of peri-implantitis for which XPhyto is targeting a late 2021 European commercial approval.

XPhyto does not make any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.

Drug Formulation & Delivery

In 2020, XPhyto’s German subsidiary, Vektor Pharma TF GmbH (“Vektor”), reported significant advancement in four therapeutic programs targeting neurological indications with significant market demand. Vektor also successfully developed a sublingual drug formulation on contract for a major generic drug manufacturer and distributor.

XPhyto will look to build on this progress in 2021, with plans to complete human pilot studies evaluating its four lead therapeutic products:

  • Rotigotine transdermal patch for Parkinson’s disease
  • CBD oral/sublingual strip for treatment resistant epilepsy
  • THC oral/sublingual strip for anorexia/nausea
  • CBD:THC (1:1) oral/sublingual strip for multiple sclerosis associated spasticity

Per its 2021 business update, the company is currently in “ongoing discussions with multiple potential commercial partners, licensors and distributors and will be reviewing monetization opportunities on a continued basis.”

Psychedelic Medicine

Psychedelic compounds are a highly promising new class of active pharmaceutical ingredient (“API”) demonstrating strong potential for a variety of mental health conditions. XPhyto is positioned to capitalize on this promise through two strategic initiatives:

  • An agreement for the development of industrial scale biotechnology processes for the production of psilocybin
  • An agreement for R&D related to multiple psychedelic compounds, including psilocybin, mescaline, LSD, MDMA and DMT, among others

XPhyto intends to advance and expand its programs focused on the industrial scale production of psychedelic API in 2021. The company also plans to launch new programs for the development of psychedelic drug formulations, with a focus on sublingual and transdermal therapeutics and the integration of these products into established clinical programs relating to mental health indications.

Management Team

Hugh Rogers is the CEO and Director of XPhyto Therapeutics Corp. He is an entrepreneur and lawyer with private and public start-up company experience in various industries and operational roles. His recent advisory work has focused on public listings and corporate restructuring. This restructuring has occurred in the life science (cell therapy and medical device) and natural resources (natural gas co-gen and conventional oil) industries. Mr. Rogers holds a bachelor’s degree in Cellular Biology and Genetics and a law degree. He is a member in good standing of the Law Society of British Colombia.

Christopher Ross is the CFO of XPhyto. He is a professional accountant with broad financial experience across numerous industries, including forestry, distribution, construction, mining and multi-family real estate. He has provided advisory services to private and public companies in the areas of financial accounting, strategic analysis, audit and taxation. Mr. Ross holds a bachelor’s degree in commerce. He is a member in good standing with the Chartered Professional Accountants Association of British Columbia.

Wolfgang Probst serves as Director of XPhyto and Managing Director of BUNKER Pflanzenextrakte GmbH. He is a seasoned management and financial consultant based in Bavaria, Germany. He has consulting experience as branch head working with private clients and corporations of high net worth. In 2017, Mr. Probst assumed the CFO role of BUNKER and continues to play a key role in its operational and financial development.

Professor Dr. Raimar Löbenberg serves as Director of XPhyto. He holds a Bachelor of Science in pharmacy from Johannes Gutenberg-University and a Ph.D. in pharmaceutics from the Johann Wolfgang Goethe-University. He is the co-founder of RS Therapeutics Inc., which concentrates on foam-based topical drug delivery systems.

Professor Dr. Thomas Beckert is the Founder and Managing Director of Vektor Pharma TF GmbH. His expertise includes the formulation and machine development of transdermal therapeutic systems and ODFs. Professor Beckert holds a Bachelor of Science in pharmacy from the University of Freiburg and a Ph.D. in pharmacy and economics from the University of Tubingen.

XPhyto Therapeutics Corp. (OTCQB: XPHYF), closed Thursday’s trading session at $1.39, up 1.966%, on 20,714 volume with 46 trades. The average volume for the last 3 months is 43,181 and the stock's 52-week low/high is $1.3125/$3.0999999.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Wednesday's trading